Insight
- Proton pump inhibitors (PPIs) are associated with an increased risk of gastric cancer, especially with the non-cardiac type.
Why this matters
- PPIs are commonly prescribed for gastric ulcer, gastroesophageal reflux disease, dyspepsia and Helicobacter pylori eradication, as well as in patients using certain medicines (, NSAIDs, etc.).
Study design
- Meta-analysis of 16 cohort and case-control studies.
- Funding: none.
Key findings
- The use of PPIs was significantly associated with gastric cancer (OR 1.75; p<0.001).
- Subgroup analysis revealed a significant increase in risk for non-cardiac gastric cancer (OR 2.14; 95% CI 1.50-3.07).
- There was no long-term effect of PPI intake on gastric cancer risk:
- <1 year: OR 2.56; 95% CI 1.41-4.64.
- 1-3 years: OR 1.47; 95% CI 1.26-1.71.
- >3 years: OR 1.58; 95% CI 1.16-2.14.
- In people receiving PPI therapy, even after eradication of H.pylori observed a higher risk of gastric cancer (OR 2.67; 95% CI 1.79-4.0).
- <1 year: OR 2.56; 95% CI 1.41-4.64.
- 1-3 years: OR 1.47; 95% CI 1.26-1.71.
- >3 years: OR 1.58; 95% CI 1.16-2.14.
Constraints
- Cohort and case-control studies were included.
- Type and dose of PPIs were not reported.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/protonenpumpen-inhibitoren-erhohen-das-magenkarzinom-risiko
Comments are closed.